CNTO 328, a monoclonal antibody to IL‐6, inhibits human tumor‐induced cachexia in nude mice
Open Access
- 4 May 2004
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 111 (4), 592-595
- https://doi.org/10.1002/ijc.20270
Abstract
IL-6 is a multifunctional cytokine implicated in several cancers. IL-6 is a growth factor for certain tumors and contributes to drug resistance, cachexia and bone resorption. Cachexia is characterized by progressive weight loss and depletion of host reserves of adipose tissue and skeletal muscle. We have developed CNTO 328 (cCLB8), a human–mouse chimeric MAb to IL-6 (Kd approx. 10−12 M) that inhibits IL-6 function. A phase I study with CNTO 328 in multiple myeloma patients demonstrated that the antibody was safe and had a circulating half-life of approximately 17 days. Since IL-6 is implicated in cachexia, we hypothesized that CNTO 328 could inhibit tumor-induced cachexia. We used 2 human tumor-induced cachexia models in nude mice. In the first model, human melanoma cells were inoculated in female nude mice. Control treated animals lost 19% (±7.7%) body weight from day 0 to day 31, whereas CNTO 328 (10 mg/kg)–treated animals lost only 1.5% (±1.3%) body weight from day 0 to day 31 (p = 0.023). In the second cachexia model, human prostate tumor cells were injected into male nude mice. By day 29, control treated animals lost 6% (±3.5%) body weight, whereas CNTO 328 (10 mg/kg)–treated animals gained 7% (±4%) body weight (p = 0.01). Since CNTO 328 blocks human IL-6 but not mouse IL-6, the data indicate that tumor cell–secreted IL-6 directly contributes to body weight loss, highlighting the potential role for CNTO 328 as an anticachectic agent.Keywords
This publication has 19 references indexed in Scilit:
- Elevation of cytokine levels in cachectic patients with prostate carcinomaCancer, 2003
- Cachexia in cancer patientsNature Reviews Cancer, 2002
- Biological Activity of a Novel Nonpeptide Antagonist to the Interleukin-6 Receptor 20S,21-Epoxy-resibufogenin-3-formateJournal of Pharmacology and Experimental Therapeutics, 2002
- Molecular analysis of lipid‐depleting factor in a colon‐26‐inoculated cancer cachexia modelInternational Journal of Cancer, 2002
- Anti‐interleukin‐6 monoclonal antibody induces regression of human prostate cancer xenografts in nude miceThe Prostate, 2001
- CYTOKINE LEVELS (IL-6 AND IFN-γ), ACUTE PHASE RESPONSE AND NUTRITIONAL STATUS AS PROGNOSTIC FACTORS IN LUNG CANCERCytokine, 1999
- Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating studyBritish Journal of Haematology, 1998
- Resistance to IL-1 anti-proliferative effect, accompanied by characteristics of advanced melanoma, permits invasion of human melanoma cellsin vitro, but not metastasis in the nude mouseInternational Journal of Cancer, 1997
- Evidence for the involvement of interleukin 6 in experimental cancer cachexia.JCI Insight, 1992
- Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexiaEuropean Journal of Cancer and Clinical Oncology, 1991